Effects of Sertraline on Circulating Markers of Oxidative Stress in Depressed Patients With Chronic Heart Failure: A Pilot Study

Michalakeas, Christos A.; Parissis, John; Douzenis, Athanasios; Nikolaou, Maria; Varounis, Christos; Andreadou, Ioanna; Antonellos, Nikolaos; Markantonis-Kiroudis, Sophia; Paraskevaidis, Ioannis; Ikonomidis, Ignatios; Lykouras, Elefterios; Kremastinos, Dimitrios Th.

doi:10.1016/j.cardfail.2011.05.004

Cited by 32 publications

(30 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevated MDA levels have also been confirmed in depressed patients suffering from chronic heart failure (Michalakeas et al, 2011) and newly diagnosed gastric adenocarcinoma (Wei et al, 2009). …”

Section: Oxidative Stress and Antioxidant Defence Biomarkersmentioning

confidence: 91%

A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers

Lopresti

Maker

Hood

et al. 2014

Progress in Neuro-Psychopharmacology and Biological Psychiatry

312

180

View full text Add to dashboard Cite

Biomarkers are regularly used in medicine to provide objective indicators of normal biological processes, pathogenic processes or pharmacological responses to therapeutic interventions, and have proved invaluable in expanding our understanding and treatment of medical diseases. In the field of psychiatry, assessment and treatment has, however, primarily relied on patient interviews and questionnaires for diagnostic and treatment purposes. Biomarkers in psychiatry present a promising addition to advance the diagnosis, treatment and prevention of psychiatric diseases. This review provides a summary on the potential of peripheral biomarkers in major depression with a specific emphasis on those related to inflammatory/immune and oxidative stress/antioxidant defences. The complexities associated with biomarker assessment are reviewed specifically around their collection, analysis and interpretation. Focus is placed on the potential of peripheral biomarkers to aid diagnosis, predict treatment response, enhance treatment-matching, and prevent the onset or relapse of major depression.

show abstract

Section: Oxidative Stress and Antioxidant Defence Biomarkersmentioning

confidence: 91%

A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers

Lopresti

Maker

Hood

et al. 2014

Progress in Neuro-Psychopharmacology and Biological Psychiatry

312

180

View full text Add to dashboard Cite

show abstract

“…(d) Malondialdehyde (MDA): MDA levels are increased in depressed patients[31] and a similar relationship has been found in depressed patients suffering from chronic heart failure[37]. (e) Isoprostanes: Levels of isoprostanes are elevated in patients suffering from depression, as demonstrated by higher urinary concentrations of 8-iso-PGF2α [38,39] and of a β-oxidant metabolite of 8-iso-PGF2α.…”

mentioning

confidence: 89%

Biomarkers of psychiatric diseases: Current status and future prospects

Kalia¹,

Silva²

2015

Metabolism

View full text Add to dashboard Cite

“…Other researchers have also reported the ability of different antidepressant drugs to modulate nitric oxide production (Horikawa et al 2010;Krass et al 2011;Liu et al 2011;Michalakeas et al 2011) and brain glutathione (Lobato et al 2010;Novío et al 2011). In depressed patients with chronic heart failure, sertraline treatment decreased the elevated plasma levels of the oxidative stress marker MDA (Michalakeas et al 2011). Our results also suggest an antioxidant property for donepezil which resulted in significant decreases in lipid peroxidation and nitrite levels and increased GSH and catalase activity.…”

Section: Discussionmentioning

confidence: 95%

Study of the effect of antidepressant drugs and donepezil on aluminum-induced memory impairment and biochemical alterations in rats

et al. 2014

View full text Add to dashboard Cite

Alzheimer's disease is the leading cause of dementia in the elderly. Depression is a common psychiatric disorder affecting individuals across life span and often arises in the context of pre-dementia, dementia, and Alzheimer's disease. The present study aimed to investigate the effects of the antidepressant drugs clomipramine (14.2 and 56.9 μmol/kg), fluoxetine (14.5 and 57.8 μmol/kg), and sertraline (14.6 and 58.4 μmol/kg) compared with acetylcholinesterase inhibitor donepezil (12 μmol/kg) on oxidative stress, memory impairment, and depressant-like behavior in a model of Alzheimer's disease induced by prolonged intraperitoneal administration of aluminum chloride (AlCl 3 ) (10 mg/kg/day for 60 days) in rats. Results indicated that the latency to find the hidden platform in Morris water maze (MWM) test increased by 100 %, while the immobility duration in forced swimming test (FST) increased by 51 % in AlCl 3 -treated rats. The administration of AlCl 3 resulted in increased brain malondialdehyde (MDA) by 58.6 % and nitric oxide (nitrite) concentrations by 71.7 %, while reduced glutathione (GSH) decreased by 35.6 % compared with the vehicle-treated group. Catalase and paraoxonase 1 (PON1) activities in the brain decreased by 41.8 and 18.3 %, respectively. Serum acetylcholinesterase (AChE) increased by 47.8 % and brain butyrylcholinesterase (BuChE) decreased by 23.1 % after AlCl 3 treatment. In AlCl 3 -treated rats, memory performance in the MWM test improved following donepezil and the highest dose of clomipramine, fluoxetine, and sertraline. The immobility duration in the FST was decreased by sertraline. Significant decrease in brain MDA occurred after treatment with clomipramine, fluoxetine, and a lower dose of sertraline. Reduced glutathione level increased by donepezil, clomipramine, and 57.8 μmol/kg fluoxetine. The level of nitric oxide decreased by donepezil (42.6 %), clomipramine (45.0 and 62.9 %), fluoxetine (21.9 and 40.9 %), and 14.6 μmol/kg sertraline (28.7 %). Catalase activity was restored by donepezil, fluoxetine, and sertraline and markedly increased by 56.9 μmol/kg clomipramine. Paraoxonase 1 activity was increased by 14.2 μmol/kg clomipramine. BuChE activity was unaltered, but AChE activity was decreased by donepezil, clomipramine, and fluoxetine compared with the AlCl 3 control group. AlCl 3 resulted in neurodegeneration (gliosis), extensive dark neurons with corkscrew dendrites, and degeneration of some Purkinje cell. Following donepezil treatment, no dark neurons were observed, while increased granular cell layer was observed after the administration of a high dose of clomipramine, fluoxetine, or sertraline. The results suggested that in rats treated with AlCl 3 , (i) donepezil, sertraline, clomipramine, and fluoxetine improve memory performance; (ii) sertraline was particularly effective in improving depressive-like behavior in this model and might be of value in the treatment of depressive symptoms associated with Alzheimer's disease; (iii) donepezil, clomipramine, and fluoxetine alleviated oxi...

show abstract

Effects of Sertraline on Circulating Markers of Oxidative Stress in Depressed Patients With Chronic Heart Failure: A Pilot Study

Cited by 32 publications

References 33 publications

A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers

A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers

Biomarkers of psychiatric diseases: Current status and future prospects

Study of the effect of antidepressant drugs and donepezil on aluminum-induced memory impairment and biochemical alterations in rats

Contact Info

Product

Resources

About